Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
UBS raises Teva price target - Globes
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
Teva started at neutral at UBS on pricing and legal concerns (NYSE:TEVA) | Seeking Alpha
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Brussels' Teva probe reveals dark side of patent protections | Financial Times
Teva Tries to Put an End to the Opioid Wars - WSJ
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Jennifer Bryan - Head of Commercial Training & Development - Teva Pharmaceuticals | LinkedIn
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
Teva stock drops on guidance, manufacturing problems - MarketWatch
As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites | Ctech
Storbank blåstempler Kåre Schultz' plan for Teva: Aktien er »for billig til at ignorere«
Teva Has Potential For 6% CAGR Ahead, UBS Says In Upgrade
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
UBS cuts estimate of Teva's opioid liability - Globes
